NasdaqGS:AUTL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Autolus Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AUTL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.4%

AUTL

2.0%

US Biotechs

2.3%

US Market


1 Year Return

0.1%

AUTL

27.6%

US Biotechs

6.7%

US Market

Return vs Industry: AUTL underperformed the US Biotechs industry which returned 26.3% over the past year.

Return vs Market: AUTL underperformed the US Market which returned 6% over the past year.


Shareholder returns

AUTLIndustryMarket
7 Day7.4%2.0%2.3%
30 Day15.9%7.4%-0.7%
90 Day100.3%25.3%17.1%
1 Year0.1%0.1%28.8%27.6%9.0%6.7%
3 Yearn/a34.6%30.2%36.7%27.8%
5 Yearn/a-3.3%-8.8%65.2%46.9%

Price Volatility Vs. Market

How volatile is Autolus Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Autolus Therapeutics undervalued compared to its fair value and its price relative to the market?

2.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AUTL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AUTL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AUTL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AUTL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AUTL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AUTL is good value based on its PB Ratio (2.3x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Autolus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-9.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AUTL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AUTL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AUTL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AUTL's revenue (74.2% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: AUTL's revenue (74.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AUTL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Autolus Therapeutics performed over the past 5 years?

-49.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AUTL is currently unprofitable.

Growing Profit Margin: AUTL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AUTL is unprofitable, and losses have increased over the past 5 years at a rate of -49.9% per year.

Accelerating Growth: Unable to compare AUTL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AUTL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: AUTL has a negative Return on Equity (-44.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is Autolus Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AUTL's short term assets ($280.9M) exceed its short term liabilities ($26.1M).

Long Term Liabilities: AUTL's short term assets ($280.9M) exceed its long term liabilities ($24.1M).


Debt to Equity History and Analysis

Debt Level: AUTL is debt free.

Reducing Debt: AUTL has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AUTL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AUTL has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 43.7% each year.


Next Steps

Dividend

What is Autolus Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AUTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AUTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AUTL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AUTL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AUTL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Chris Itin (56yo)

4.33yrs

Tenure

US$3,979,369

Compensation

Dr. Christian Martin Itin, also known as Chris, Ph.D., has been the Chief Executive Officer of Autolus Therapeutics Plc. and Autolus Limited since March 3, 2016. Dr. Itin has been Director of Autolus Holdi ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD5.01M) is above average for companies of similar size in the US market ($USD3.16M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Christian Itin
Chairman & CEO4.33yrsUS$3.98m2.04% $17.1m
Martin Pulé
Founder5.92yrsno data1.34% $11.2m
Andrew Oakley
CFO & Senior VP2.08yrsno datano data
Christopher Vann
Senior VP & COO3.75yrsno data0.21% $1.8m
Matthias Alder
Senior VP3yrsno data0.24% $2.0m
Muhammad Al-Hajj
Senior Vice President of Translational Sciences3yrsno datano data
Vijay Peddareddigari
Senior VP & Chief Medical Officer4.33yrsno data0.087% $727.0k
Adam Hacker
Senior Vice President of Regulatory Affairs & Quality1.75yrsno datano data
David Brochu
Senior Vice President of Product Delivery0.75yrno datano data
Lucinda Crabtree
Vice President of IR & Corporate Communicationsno datano datano data

3.0yrs

Average Tenure

55yo

Average Age

Experienced Management: AUTL's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christian Itin
Chairman & CEO4.33yrsUS$3.98m2.04% $17.1m
Cynthia Butitta
Independent Non-Executive Director2.08yrsUS$461.13kno data
John Berriman
Independent Non-Executive Director2.08yrsUS$440.72k0.26% $2.2m
Martin Murphy
Independent Non-Executive Director2.08yrsUS$376.92kno data
Joseph Anderson
Independent Non-Executive Director2.08yrsUS$381.42kno data
Kapil Dhingra
Independent Non-Executive Director2.08yrsUS$425.72k0.14% $1.2m
Linda Bain
Independent Non-Executive Director2.08yrsUS$510.99kno data

2.1yrs

Average Tenure

61yo

Average Age

Experienced Board: AUTL's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.


Top Shareholders

Company Information

Autolus Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Autolus Therapeutics plc
  • Ticker: AUTL
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$835.967m
  • Shares outstanding: 52.25m
  • Website: https://www.autolus.com

Number of Employees


Location

  • Autolus Therapeutics plc
  • Forest House
  • 58 Wood Lane
  • London
  • Greater London
  • W12 7RZ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AUTLNasdaqGS (Nasdaq Global Select)YesSPON ADSUSUSDJun 2018
6A3ADB (Deutsche Boerse AG)YesSPON ADSDEEURJun 2018

Biography

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/09 00:02
End of Day Share Price2020/07/08 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.